Treating Geographic Atrophy Remains a Tough Call for Ophthalmologists as They Voice Hesitancy to Prescribe Complement Inhibitors
Belite Bio, Inc - American Depositary Shares (BLTE)
Company Research
Source: GlobeNewswire
Exton, Pennsylvania, June 27, 2024 (GLOBE NEWSWIRE) -- Prior to 2023, there was no treatment for GA, a progressive form of dry age-related macular degeneration that results in blindness. That changed in early 2023 when Apellis gained FDA approval for Syfovre, followed by Iveric Bio/Astellas’ approval for Izervay later in the year. Both treatments are classified as complement inhibitors, administered via monthly/every other month intravitreal injections, and aim to prevent further vision loss. However, neither fully prevents nor reverses the progression of GA, making it difficult for some physicians and patients to see the value in these new treatment options. Shortly after Syfovre's launch, the American Society of Retina Specialists (ASRS) issued a warning about potential vascular adverse events, which led to a cautious approach among eye care professionals. This caution, reflected in Spherix Global Insights report series, contributed to some ophthalmologists' reluctance to prescr
Show less
Read more
Impact Snapshot
Event Time:
BLTE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLTE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLTE alerts
High impacting Belite Bio, Inc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BLTE
News
- Stargardt Disease Drug Pipeline Research 2024: Therapeutic Assessment by Product Type, Stage, Route of Administration, and Molecule Type [Yahoo! Finance]Yahoo! Finance
- Belite Bio, Inc (NASDAQ: BLTE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Belite Bio, Inc (NASDAQ: BLTE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $59.00 price target on the stock.MarketBeat
- Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in JapanGlobeNewswire
- Inherited Retinal Disease Market Size and Share to Grow by 2034, Assesses DelveInsight | Key Companies - Spark Therapeutics, Alkeus Pharmaceuticals, Novartis Pharmaceuticals, Beacon Therapeutics, GenSight Biologics, Ocugen, AbbViePR Newswire
BLTE
Earnings
- 5/13/24 - Beat
BLTE
Sec Filings
- 6/4/24 - Form 144
- 5/30/24 - Form 144
- 5/30/24 - Form 144
- BLTE's page on the SEC website